Associated tags: ICE, Patient, Cancer, ROCK, Biotechnology, Pharmaceutical industry, Affimer, NK, Vaccine
Locations: KOREA, SPAIN, JAPAN, CA, MANNHEIM,, DE, GERMANY, NETHERLANDS, SEOUL, CHICAGO, NY, NEW YORK
Retrieved on:
Wednesday, January 3, 2024
MANNHEIM, Germany, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that it has reached a definitive agreement to sell its wholly-owned subsidiary, AbCheck s.r.o., to Ampersand Biomedicines.
Key Points:
- MANNHEIM, Germany, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that it has reached a definitive agreement to sell its wholly-owned subsidiary, AbCheck s.r.o., to Ampersand Biomedicines.
- Under the terms of the agreement, Ampersand Biomedicines will acquire AbCheck for a purchase price of $6 million, consisting of $5 million in cash to be paid in two tranches, and $1 million in Ampersand common stock, subject to certain adjustments and a holdback.
- Affimed is also entitled to receive milestone payments from a pre-existing AbCheck partnership.
Retrieved on:
Monday, December 11, 2023
Stomach,
EST,
Hepatocellular carcinoma,
RECIST,
EGFR,
Progression-free survival,
Cancer,
Pancreatic cancer,
Toxicity,
Cholangiocarcinoma,
Webcast,
Patient,
Safety,
NSCLC,
Pharmaceutical industry The data update as of December 6th, 2023, includes 15 patients from the EGFR-wildtype NSCLC cohort with a median of 2 prior lines of therapy.
Key Points:
- The data update as of December 6th, 2023, includes 15 patients from the EGFR-wildtype NSCLC cohort with a median of 2 prior lines of therapy.
- The combination of AFM24 with atezolizumab showed encouraging signals of clinical activity, including 1 unconfirmed CR, 3 PRs (1 confirmed, 2 unconfirmed) and 7 patients exhibiting SD.
- Considering the low ORR reported on atezolizumab monotherapy in checkpoint inhibitor-relapsing and refractory patients, Affimed believes the clinical activity observed in AFM24-102 is likely due to the synergy of AFM24 with atezolizumab.
- AFM24 has demonstrated a positive safety and tolerability profile as both a monotherapy and in combination therapy.
Retrieved on:
Monday, December 11, 2023
Patient,
EST,
Haematopoietic system,
Dor,
EFS,
MD Anderson Cancer Center,
Graft-versus-host disease,
Society,
Cancer,
ASH,
HL,
CRS,
PST,
Webcast,
Safety,
University,
BV,
Pharmaceutical industry Affimed will host a webcast following the presentation to review the data and provide a strategic update on acimtamig’s future development.
Key Points:
- Affimed will host a webcast following the presentation to review the data and provide a strategic update on acimtamig’s future development.
- A total of 42 patients were enrolled in the study with 36 patients treated at the RP2D.
- 32 of the 36 patients treated at the RP2D were HL patients.
- For the HL patients treated at the RP2D, median EFS was 9.8 months - with 84% patients alive at 12 months.
During the call, the Company will also provide a clinical data update from the AFM24-102 trial.
Key Points:
- During the call, the Company will also provide a clinical data update from the AFM24-102 trial.
- The conference call will be available via phone and webcast.
- The live audio webcast of the call will be available in the “Webcasts” section on the “Investors” page of the Affimed website at https://www.affimed.com/investors/webcasts-and-corporate-presentation/ .
- Note: To avoid delays, we encourage participants to dial into the conference call 15 minutes ahead of the scheduled start time.
Retrieved on:
Tuesday, November 14, 2023
Webcast,
Record,
Safety,
Annual general meeting,
Cytokine release syndrome,
Research,
Type,
Silicon Valley Bank,
ASH,
Non-Hodgkin lymphoma,
CRS,
International,
Bank statement,
Book,
Silicon,
Insurance,
Patient,
Genentech,
FDA,
Hodgkin lymphoma,
Lung cancer,
International Financial Reporting Standards,
GVHD,
Monroe Dunaway Anderson,
International Accounting Standards Board,
IASB,
Cholangiocarcinoma,
ORR,
Roivant Sciences,
Cancer,
Trial of the century,
Financial toxicity,
Haematopoietic system,
HL,
EST,
AML,
Society,
NHL,
PTCL,
NK,
NSCLC,
Cryptocurrency,
Medical device,
Vaccine,
Pharmaceutical industry,
Rare-earth element,
Audit,
Euro,
Affimer MANNHEIM, Germany, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today reported financial results and provided an update on clinical and corporate progress for the third quarter of 2023.
Key Points:
- MANNHEIM, Germany, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today reported financial results and provided an update on clinical and corporate progress for the third quarter of 2023.
- Total revenue for the quarter ended September 30, 2023, was €2.0 million compared with €14.9 million for the quarter ended September 30, 2022.
- Affimed prepares and reports consolidated financial statements and financial information in accordance with IFRS as issued by the IASB.
- Affimed will host a conference call and webcast on November 14, 2023, at 8:30 a.m. EST / 14:30 CET to discuss third quarter 2023 financial results and corporate developments.
Retrieved on:
Thursday, November 9, 2023
WHO,
FDA,
International,
PTCL,
INN,
Affimer,
Cell,
Neoplasm,
World Health Organization,
Cancer,
Patient,
Pharmaceutical industry MANNHEIM, Germany, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that the International Nonproprietary Names (INN) Expert Committee of the World Health Organization (WHO) has selected "acimtamig" for the nonproprietary name of the Company’s investigational drug for CD30-positive Lymphomas, previously known as AFM13.
Key Points:
- MANNHEIM, Germany, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that the International Nonproprietary Names (INN) Expert Committee of the World Health Organization (WHO) has selected "acimtamig" for the nonproprietary name of the Company’s investigational drug for CD30-positive Lymphomas, previously known as AFM13.
- Following the WHO nomenclature scheme, the name recognizes the drug as a tumor targeting bispecific antibody.
- “Selection of the INN acimtamig by the WHO is an important milestone in the clinical development of AFM13 with initiation of the LuminICE-203 study underway,” said Dr. Adi Hoess, Chief Executive Officer at Affimed.
- “It adds to the momentum of the fast track designation awarded by the FDA earlier this year to the acimtamig and AlloNK® combination.
Retrieved on:
Tuesday, November 7, 2023
MANNHEIM, Germany, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will release third quarter 2023 results and corporate update on Tuesday, November 14, 2023.
Key Points:
- MANNHEIM, Germany, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will release third quarter 2023 results and corporate update on Tuesday, November 14, 2023.
- The Company will host a conference call at 8:30 a.m. EST / 14:30 CET.
- The live audio webcast of the call will be available in the “Webcasts” section on the “Investors” page of the Affimed website at https://www.affimed.com/investors/webcasts-and-corporate-presentation/ .
- Note: To avoid delays, we encourage participants to dial into the conference call 15 minutes ahead of the scheduled start time.
IZI,
Society for Immunotherapy of Cancer,
Affimer,
Engineering,
Poster,
SITC,
Immunotherapy,
ADCC,
NK,
Cell therapy,
Society,
Cancer,
Patient,
Fraunhofer Society,
Fertilizer,
Vaccine “This is the first direct comparison of NK cells redirected by Affimed’s ICE® with CAR-NK cells,” said Dr. Arndt Schottelius, Chief Scientific Officer at Affimed.
Key Points:
- “This is the first direct comparison of NK cells redirected by Affimed’s ICE® with CAR-NK cells,” said Dr. Arndt Schottelius, Chief Scientific Officer at Affimed.
- The combination of allogeneic NK cells with ICE® molecules represents the most straightforward way to generate potent and targeted NK cells.
- The combination of the ICE® molecule with NK cells or CAR-NK cells enhanced antibody-dependent cellular cytotoxicity (ADCC) against tumor cells and mediated elevated levels of degranulation when compared to NK cells or CAR-NK cells alone.
- In conclusion, the combination of NK cells with ICE® represents a straight-forward way to potently target and activate NK cells.
Retrieved on:
Thursday, November 2, 2023
Cord blood,
Patient,
Lymphoma,
HL,
PTCL,
EST,
Cell,
GVHD,
Affimer,
Society,
ASH,
CFGB-FM,
PST,
NK,
Relapse,
Cytokine release syndrome,
Abstract,
Annual general meeting,
Natural killer T cell,
ORR,
EFS,
Haematopoietic system,
University,
Exposition,
Safety,
CRS,
Cancer,
Peripheral T-cell lymphoma,
MD Anderson Cancer Center,
Investigational New Drug,
Pharmaceutical industry,
Vaccine,
Leukemia A total of 42 patients were enrolled in the study with 36 patients treated at the RP2D.
Key Points:
- A total of 42 patients were enrolled in the study with 36 patients treated at the RP2D.
- All patients were heavily pretreated and refractory to their most recent line of therapy with active progressive disease at the time of enrollment.
- A more in-depth analysis of the data and updated EFS/OS data using a later cut-off date will be presented during Dr. Nieto’s oral presentation.
- The second presentation will be a poster featuring the design of Affimed’s phase 2 LuminICE-203 clinical trial investigating AFM13 in combination with Artiva’s AlloNK® (also known as AB-101), an allogeneic, non-genetically modified NK cell therapy candidate.
Retrieved on:
Wednesday, November 1, 2023
MANNHEIM, Germany, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that the Company’s management will participate in the following investor conferences during the month of November 2023.
Key Points:
- MANNHEIM, Germany, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that the Company’s management will participate in the following investor conferences during the month of November 2023.
- Truist Securities BioPharma Symposium (November 8-9, 2023)
Jefferies London Healthcare Conference (November 14-16, 2023)
For more information or to schedule a one-on-one meeting with Affimed’s management, please contact your event representative or Alex Fudukidis via email at [email protected] or phone at +1 (917) 436-8102.
